• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Next-generation sequencing and its clinical application

    2019-02-18 00:52:52DahuiQin
    Cancer Biology & Medicine 2019年1期

    Dahui Qin

    Molecular Diagnostic Laboratory, Department of Pathology, Moffitt Cancer Center, Tampa 33612-9416, FL, USA

    Next-generation sequencing (NGS) is a new technology used for DNA and RNA sequencing and variant/mutation detection. NGS can sequence hundreds and thousands of genes or whole genome in a short period of time. The sequence variants/mutations detected by NGS have been widely used for disease diagnosis, prognosis, therapeutic decision, and follow up of patients. The capacity of its massive parallel sequencing offers new opportunities for personalized precision medicine.

    Introduction

    NGS1-4is a new technology for DNA and RNA sequencing and variant/mutation detection. This technology combines the advantages of unique sequencing chemistries, different sequencing matrices, and bioinformatics technology. Such a combination allows a massive parallel sequencing of various lengths of DNA or RNA sequences or even whole genome within a relatively short period of time. It is a revolutionary sequencing technology after Sanger sequencing5.

    NGS involves several major steps in sequencing. For example, DNA NGS involves DNA fragmentation, library preparation, massive parallel sequencing, bioinformatics analysis, and variant/mutation annotation and interpretation.

    DNA fragmentation

    DNA fragmentation is used to break the targeted DNA into many short segments, usually 100-300 bp in length. Different methods can be used to achieve this. DNA can be fragmented using mechanical methods, enzymatic digestion6, or other methods. For example, sonication can be used to break DNA into short segments. The short segments relevant to the targeted DNA sequences are pulled out using specific complementary probes of different designs7,8. This method is usually referred to as hybridization capture assay. Another method involves polymerase chain reaction (PCR)amplification. In this method, many pairs of primers are used to amplify the targeted DNA segments using PCR. The PCR products serve as short segments of targeted DNA. This method is usually called amplicon assay9,10. The DNA segments are then used for library preparation.

    Library preparation

    Library preparation is a process by which DNA segments are modified so that each DNA sample can have a samplespecific index like sample identification which helps to identify the patient from whom DNA sequencing was performed. This process also allows the sequencing adaptors to be added to the DNA segments. Such modification allows the sequencing primers to bind to all the DNA segments and enables massive parallel sequencing later.

    Sequencing

    Massive parallel sequencing is performed using an NGS sequencer. The library is uploaded onto a sequencing matrix in a certain sequencer. Different sequencers have different sequencing matrices. For example, Illumina NGS sequencer uses flow cells and Ion Torrent NGS sequencer uses sequencing chips. However, its goal is the same, which is to allow massive parallel sequencing of all the DNA segments at the same time. The sequence information generated from such massive parallel sequencing is analyzed using bioinformatics software.

    Bioinformatics analysis and data interpretation

    Bioinformatics analysis is a process involving base calling,read alignment, variant identification, and variant annotation11. During this process, the sequence information is compared to a human genome reference sequence to identify whether there are any variants/mutations in the targeted sequences. All information from each sequenced segment is pieced together to generate final sequencing results for the full length of the targeted DNA. The final sequencing results are sent back to the user for interpretation.

    The annotation and interpretation processes are set to identify each variant and their possible biological/clinical significance.

    Clinical application of NGS

    Necessity of NGS technology

    One of the advantages of NGS is to interrogate many targets at the same time on the scale of hundreds and thousands or even millions of targets. Such capacity gives NGS huge potential application in clinical settings. For example, in cancer patient care, any given tumor may have multiple mutations. If the traditional molecular assays are used in such clinical settings, multiple assays may have to be performed for multiple mutations. A larger amount of tissue may be needed for these multiple assays. Using NGS technology, these targets can be interrogated in one test.Therefore, less tissue is needed and the results of dozens and hundreds of DNA targets are obtained from one test. In recent years, scientific research has revealed an increasing number of mutations in different diseases. For example,different mutations have been discovered in different hematopoietic leukemias. The mutations in NPM1 and CEBPA of a RUNX1 have been found in acute myeloid leukemia (AML) associated with different entities of AML subtypes12. In myelodysplastic syndrome, many mutations have been found associated with different clinical implications. The genes harboring these mutations include but are not limited to TET2, DNMT3a, ASXL1, EZH2,SF3B1, SRSF2, U2AF1, ZRSR2, TP53, STAG2, NRAS, CBL,JAK2, NF1, RUNX1, ETV6, IDH1, IDH2, SETBP1, PHF6,BCOR, STAT3, and PPM1D13.

    In a patient's sample, the leukemic cells bearing the same mutation are believed to be originated from one clone. A patient's sample with many mutations may have more than one clone of leukemic cells. A leukemic disease may not only have more than one clone of leukemic cells, and the clones may change during the course of the disease. Such phenomenon is referred to as clonal evolution14-18. A similar phenomenon has been observed in solid tumors too17,19. This observation has changed the old one-tumor one-mutation concept. A solid tumor may have multiple mutations. These mutations can originate from one clone or multiple clones.This is called tumor mutation heterogeneity20. Therefore, in cancer patient care, multiple gene mutations need to be tested very often. Due to clonal evolution, many different gene mutations need to be tested during follow-up. Besides,not only solid tumors may have multiple mutations, but metastatic tumors may also have mutations different from that of the primary tumor21,22. Such findings also indicate that multiple mutations need to be tested by diagnostic and follow-up molecular tests. With the advent of immunotherapy, tumor mutation burden has become an important parameter to be tested23. This again needs to investigate numerous mutations in a tumor sample. The traditional molecular test methods are not useful for such needs. Therefore, NGS technology becomes necessary for such tasks in patient care. Moreover, in the current medical practice, although biopsy specimens become smaller and smaller, more information related to mutation need to be extracted from small biopsy samples. In many cases, it is impossible for the traditional molecular tests to meet such needs. NGS has evolved to meet such needs. By massive parallel sequencing, NGS technology can test multiple samples and multiple targets at the same time. Therefore, it increases the turnaround time of the molecular tests. It has become clear that NGS technology is an important tool in personalized precision medicine. It provides information for disease diagnostic classification, selection of therapeutic agents, and prognostic evaluation. However, the application of NGS in clinical settings involves challenges.

    The scope of NGS technology

    For a proper clinical application of NGS, multiple necessary measures have to be followed. Guidelines and recommendations regarding the use NGS technology for clinical tests have been published by the College of American Pathology (CAP)24, Association of Molecular Pathology(AMP)25, and other agencies26.

    NGS can be performed at different levels. It can be used for whole-genome sequencing. At this level, almost all the nucleotide in the genome, including chromosomal DNA and the mitochondrial DNA, are interrogated. Whole genome sequencing is used more often in research and less common in clinical settings. When used in clinical settings, it is used more often for constitutional genetic diseases, rather than for cancer somatic mutations. It is especially useful for the diagnosis of some rare genetic diseases. For example, when a genetic disease is suspected but no specific mutation has been identified by other molecular tests. In such cases, whole genome sequencing may provide additional information in terms of disease-associated mutations. Whole genome sequencing is used less frequently for cancer somatic mutation because the average depth in whole genome sequencing is limited. In a certain tumor, allelic mutation frequencies may vary and the percentages of tumor cells in different specimens may also vary. Detection of different mutations with different allelic frequencies in such settings often need deep sequencing and that is very challenging for the whole genome sequencing method.

    NGS assay can be used for whole exome sequencing. The entire coding region of all axons of an organism including any cell types can be sequenced. In human, that is about 1%of the human genome and is more often used in research.

    NGS can also be performed at transcriptome level which includes entire assembly of RNA transcripts in a given cell type including mRNA, rRNA, tRNA, micro-RNA, and noncoding RNA. Unlike DNA sequencing, this is called RNA sequencing. Specially designed mRNA sequencing is also often used to detect fusion genes.

    The most commonly used NGS assay for cancer patients is targeted panel sequencing which usually interrogates dozens or hundreds of targeted genes. Such targeted NGS assays are usually designed for a disease or a category of diseases, for example, a panel designed for myeloid leukemia or a panel designed for carcinoma. Compared to whole genome sequencing, such targeted panel has only limited targets.Therefore, it allows a lot more depth in sequencing, which is necessary to cover different mutations with different allelic mutation frequencies.

    Determine target genes for NGS clinical application

    The clinical application of NGS testing involves several aspects of work. The first step is to determine what genetic mutations need to be interrogated. That is usually based on what disease or diseases the particular NGS testing is designed for. Taking cancer patient as an example, the first thing that needs to do is to check the current guidelines for the disease or diseases to identify the targeted gene mutations that are included in the guideline as the standard of care. For example in non-small cell lung cancer, the guidelines indicate that EGFR, KRAS, BRAF, MET, RET, and Her2 mutations,and ALK and ROS1 translocations are clinically significant and need to be tested27. Cancer mutation research is a very active field and new discoveries are made every day.Therefore, literature needs to be reviewed to identify other potential mutations that are not yet included in the guideline but are potentially significant in clinical settings. For example, PIK3CA, NRAS, AKT1, MAP2K1, NTRK, and DDR2 mutations may have potential clinical significance in a small portion of non-small cell carcinoma patients28-31, and therefore, need to be considered whether to be included. It will also be beneficial for the laboratories to communicate with the clinicians of each subspecialty to get their feedback.By doing so, a list of mutations to be interrogated can be generated. NGS assay designed for such a group of gene mutations is usually called an NGS panel.

    Determine NGS method for clinical application

    The next step is to identify an appropriate NGS method for NGS panel. There are different NGS methods available. For a well-defined gene panel, an amplicon assay9,32,33can be used.However, if some targeted genes are difficult for an amplicon assay to work, a different method can be used, such as hybridization capture assay34. For example, if we are designing a panel for AML patients, CEBPA mutations and FLT3 mutations should be included in this panel. It is well known that CEBPA gene has high GC content which poses a challenge for an amplicon assay35. FLT3 mutations usually consist of different sizes of internal tandem duplicates. This is also challenging for an amplicon assay, which usually sequences a fixed size of amplicons. In such a case, a hybridization capture assay may work better. Once an NGS method is chosen for a clinical application, one needs to decide what type of specimen will be tested25. Will it be fresh tissue or formalin fixed paraffin-embedded (FFPE) tissue? If an NGS assay is designed for hematological malignancy, it will be more likely to test fresh tissue samples. On the other side, if an NGS assay is designed for a solid tumor, it will be more likely to test FFPE samples. FFPE samples are usually provided as unstained slides with an H&E stained slide,which usually involves microscopic review and micro/macrodissection of the samples before DNA extraction. Sometimes,a panel may be designed for both fresh tissue and FFPE tissue based on its application. The next step is to establish the standard operation procedure (SOP). This involves writing up an SOP and performing preliminary tests to fine-tune the SOP. The SOP should include wet lab procedures and dry lab(bioinformatics pipeline) procedures.

    Validation of NGS test for clinical application

    After the method of NGS assay is decided, the assay needs to be validated in a CLIA certified laboratory. The validation consists of several aspects of work, including ensuring assay accuracy, precision, reportable range, reference range,analytical sensitivity, and specificity25. A validation plan needs to be laid out. The validation plan usually defines what positive and negative control samples are going to be used.The positive and negative samples can also be mixed at different ratios to constitute the positive controls with different allelic mutation frequencies. Such controls will be used to test the assay sensitivity. Ideally, the positive controls will include different types of mutations, for example, single nucleotide mutations, deletions, and insertions. As for the deletions and insertions, the deletion and insertion sizes should be considered. Normally, Larger the deletion and insertion is, the more difficult it will be for NGS assay to interrogate. The validation plan also needs to define how many samples need to be tested. These are usually patient samples that have been tested in another CLIA certified lab.The number of samples that needs to be tested depends on multiple factors. One of them is a variation of the test results.More variation in the test results requires more samples.Generally speaking, guidelines indicate that if we want to be 95% confident for at least 95% reliability, the minimum number of samples needed is 5925.

    The validation process evaluates analytical sensitivity,specificity, accuracy, precision, limit of detection, sequencing depth, and allelic frequency cut off.

    Analytical sensitivity is a parameter that reflects the percentage of positive samples that are identified as true positive by a validated assay. Another relevant parameter is the limit of detection (LOD). LOD could be further defined as the lower limit of detection (LLOD), which reflects the lowest variant allele frequency (VAF) of a certain mutation at which 95% of the samples with such VAF would be reliably detected25,36. Normally, the lower the LLOD, the higher is the sensitivity. Analytical specificity is a parameter that reflects the percentage of negative samples that are identified as true negative by a validated assay. Accuracy is a parameter that reflects the concordance of the detected mutations and the expected mutations. Precision is a parameter that reflects the tendency of achieving the same results among different users and different runs25,36-38. Sequencing depth is defined as the number of reads of a certain targeted sequence. In an NGS assay, the sequencing depth for different targets may vary.Therefore, two different terms are introduced in describing the sequencing depth, namely, average depth and minimal depth. The average depth reflects the overall sequencing depth for a certain assay. The minimal depth indicates the lowest sequencing depth required to obtain reliable results for all the intended targets. The allelic frequency cut off is obtained during the validation process, which should allow the detection of real variants and exclusion of false ‘variants'due to a noisy background. AMP has issued a guideline for such validation process25.

    The validation plan is usually carried out in a CLIA certified laboratory. The samples need to be tested by at least two different technologists and need to be tested at different runs to evaluate repeatability/reproducibility. The data will be analyzed through a certain bioinformatics pipeline. The results of data analysis are used to define the report reference range and the limit of detection. During validation, the quality control matrix also needs to be determined. For example, the quality and quantity of nucleic acid needed for the assay will be determined. The library quantitation and qualification will also be determined. Other quality control matrices including depth of coverage (average depth and minimal depth), uniformity of coverage, cluster density and alignment passing rate, base call quality scores, mapping quality, duplication rate, and strand bias will also be determined. A discussion on the details of these matrices is beyond the scope of this article. These quality control matrices will ensure the quality of the test results25,36-38. The quality control matrix data should be included in the validation document. The guidelines usually recommend the following components to be included in the documentation:purpose of the clinical test, acceptable clinical sample types,rationale for the inclusion of specific genes, methodological approach, types and sources of reagents and testing instrumentation, software of bioinformatics analysis used for data processing and analysis, detailed step by step testing procedure (SOP), validation sample description,optimization and familiarization results, validation results,performance characteristics, assay acceptance and rejection criteria, assay limitations, quality control/assurance matrix,and other information as the medical director deems necessary25.

    The interpretation of NGS testing results is challenging.NGS testing may identify many variants. The clinical significance of these variants may vary. For some variants, the clinical significance is well known. However, for some other variants, the clinical significance is not known or not certain since these variants might have not been reported before or have only been reported rarely. The method of interpretation of NGS results is a hot topic in the discussion. A reasonable approach may consist of several steps. The first step is to follow the current guidelines. For example, in the case of tumor NGS testing, the National Comprehensive Cancer Network (NCCN) guidelines can be used for interpretation.Other relevant guidelines can also be used. The guidelines usually provide a list of genes and mutations that could be clinically significant for diagnosis, prognosis, molecular target therapies, and immunotherapies. The second step is to stay updated with the current scientific discoveries. Since new discovery emerges frequently in the gene variant detection, it is necessary to review the current literature while evaluating the clinical significance of the variants/mutations detected in the NGS test. There are also other resources, for example, the databases that are often freely available on the Internet (http://www.cbioportal.org/, http://www.uniprot.org/, https://www.ncbi.nlm.nih.gov/SNP/, http://evs.gs.washington.edu/EVS/, http://exac.broadinstitute.org/gene/ENSG00000171456, http://cancer.sanger.ac.uk/cosmic/,https://civicdb.org/home, https://www.ncbi.nlm.nih.gov/clinvar/, etc.). These databases contain a huge amount of data related to the features and biological/clinical significance of the variants/mutations.These databases often provide links for inter-database reference. Since no database is perfect, caution needs to be taken while using information from any databases.

    After an NGS assay starts in a laboratory, the quality matrix should be continuously monitored. The test results should also be continuously monitored in the context of the clinical setting and by doing biannual proficiency tests to ensure the reliability of the test results.

    Other NGS clinical applications

    NGS clinical application is not limited to diagnosis. It is also widely used in identifying mutation targets for targeting therapy and in identifying a high-risk population for certain hereditary cancers. Over the past few years, numerous molecular targeting drugs have been developed and there are more to come39. For example, the genes associated with melanoma therapy could include, but not limited to, BRAF,KIT, NRAS, NF1, GNAQ, CDK4, MITF and PD-140. The genes associated with lung cancer therapy could include, but not limited to, EGFR, KRAS, BRAF, NRAS, PIK3ca, ROS1,MEK, VEGFA, ALK, MET, ERBB2, and ERBB427,41.Therefore, there is a need to identify different mutation targets for targeted therapy. NGS assay is well fit for such tasks. NGS assay has important applications in hereditary cancer diagnosis or risk population assessment. Since the variant allelic frequencies of hereditary cancers are usually around 50% or 100%, the detection of such genetic changes needs less depth of sequencing when compared to those in cancers. Therefore, more targeted genes can be included in a panel of a certain size. This is especially useful in assessing high risk population in hereditary cancers42,43, for example,BRCA1, BRCA2, CDH1, PTEN, TP53, STK11, PALB2, ATM,CHEK2, MUTYH, BARD1, MRE11A, NBN, RAD50, RAD51C,RAD51D, and NF1 are used for breast cancer42.

    The clinical application of NGS also includes tests for tumor mutation burden and microsatellite instability, and variants/mutations from cell-free circulating DNA. The cellfree circulating DNA is sometimes called “l(fā)iquid biopsy”44-49.It is known that many solid tumors shed their DNA, which may end up in the bloodstream or other body fluids. To a certain extent, such DNA can serve as representative samples for the primary tumors. Testing such DNA can generate information on mutations similar to that obtained from tissue biopsies. Therefore, sampling cell-free DNA is sometimes called “l(fā)iquid biopsy.” The samples of “l(fā)iquid biopsy” are usually plasma or other body fluids, which are usually easily accessible. This is especially useful for those tumors that are difficult or impossible to biopsy. However,“l(fā)iquid biopsy” is not without challenges. Different tumors shed DNA differently. A certain tumor at different stage may shed DNA differently. Numerous “l(fā)iquid biopsy” studies have been carried out for different tumors50-57. NGS assay has been used for liquid biopsy testing. For NGS assay in “l(fā)iquid biopsy”, the key issue is the test sensitivity. Different methods can be used to improve NGS sensitivity. One of these is to reduce a noisy background. For example, a molecular bar code can be used to label the originally targeted molecules.Such a label can be used later to eliminate a noisy background in order to increase the sensitivity. NGS testing“l(fā)iquid biopsy” can also be used in non-invasive prenatal testing58-60. There is no doubt that NGS testing is a powerful and revolutionary technology which offers a great contribution to personalized and precision medicine.

    Conflict of interest statement

    No potential conflicts of interest are disclosed.

    丰满饥渴人妻一区二区三| 多毛熟女@视频| 国产精品国产三级专区第一集| 午夜影院在线不卡| 97人妻天天添夜夜摸| 免费黄色在线免费观看| 国产成人免费观看mmmm| 五月开心婷婷网| 国产日韩欧美亚洲二区| 国产乱来视频区| 国产精品一区二区在线不卡| 欧美精品一区二区大全| 尾随美女入室| 美女午夜性视频免费| 777久久人妻少妇嫩草av网站| 啦啦啦中文免费视频观看日本| 成人国语在线视频| 国产精品偷伦视频观看了| 免费观看av网站的网址| 国产在线视频一区二区| 欧美日韩av久久| 日本av手机在线免费观看| 国产成人91sexporn| 成人毛片a级毛片在线播放| 国产毛片在线视频| 伊人久久国产一区二区| 午夜激情av网站| 亚洲 欧美一区二区三区| 久久精品久久久久久噜噜老黄| 一级毛片黄色毛片免费观看视频| 捣出白浆h1v1| 亚洲精品日本国产第一区| www.精华液| 欧美精品人与动牲交sv欧美| 免费看不卡的av| 久久久久久人人人人人| 午夜91福利影院| 男女高潮啪啪啪动态图| 国产极品粉嫩免费观看在线| 午夜福利在线观看免费完整高清在| 天天操日日干夜夜撸| 国产淫语在线视频| 纯流量卡能插随身wifi吗| 亚洲四区av| 人人妻人人添人人爽欧美一区卜| 亚洲av男天堂| 久久99精品国语久久久| 成人亚洲欧美一区二区av| 精品人妻在线不人妻| 狠狠精品人妻久久久久久综合| 色婷婷久久久亚洲欧美| 成人漫画全彩无遮挡| 最近最新中文字幕免费大全7| 久久久精品国产亚洲av高清涩受| 在线天堂中文资源库| 天天影视国产精品| av在线老鸭窝| 久久国产精品男人的天堂亚洲| 最近的中文字幕免费完整| 啦啦啦中文免费视频观看日本| 亚洲国产欧美在线一区| 日韩精品有码人妻一区| 日韩av不卡免费在线播放| 国产熟女欧美一区二区| 亚洲成av片中文字幕在线观看 | 性色av一级| 侵犯人妻中文字幕一二三四区| 国产精品久久久久成人av| 国产激情久久老熟女| 欧美日韩精品成人综合77777| 久久久亚洲精品成人影院| 看免费成人av毛片| 深夜精品福利| 女的被弄到高潮叫床怎么办| 久久久久网色| 国产成人a∨麻豆精品| 在线观看国产h片| 国产一区二区在线观看av| 亚洲av中文av极速乱| 中文字幕另类日韩欧美亚洲嫩草| 亚洲久久久国产精品| 精品国产一区二区三区四区第35| 亚洲国产成人一精品久久久| 欧美亚洲 丝袜 人妻 在线| 狠狠婷婷综合久久久久久88av| 日本黄色日本黄色录像| 午夜免费观看性视频| 丝袜在线中文字幕| 欧美日韩视频精品一区| 18+在线观看网站| 国产淫语在线视频| 久久精品国产鲁丝片午夜精品| 国产精品久久久久久久久免| 欧美日韩精品网址| 一区二区三区乱码不卡18| 91精品国产国语对白视频| 亚洲欧洲精品一区二区精品久久久 | 久久久久精品久久久久真实原创| 亚洲av国产av综合av卡| 中文字幕人妻丝袜制服| 精品酒店卫生间| 人人妻人人爽人人添夜夜欢视频| 精品国产一区二区三区四区第35| 99久久人妻综合| 香蕉精品网在线| 青春草国产在线视频| 水蜜桃什么品种好| 热99国产精品久久久久久7| 色播在线永久视频| 日本爱情动作片www.在线观看| av又黄又爽大尺度在线免费看| 日韩精品有码人妻一区| 1024视频免费在线观看| 亚洲av国产av综合av卡| 丝袜美腿诱惑在线| 伦理电影大哥的女人| 日韩,欧美,国产一区二区三区| 老汉色av国产亚洲站长工具| 老熟女久久久| 黄网站色视频无遮挡免费观看| 午夜福利影视在线免费观看| 男男h啪啪无遮挡| 色视频在线一区二区三区| 欧美另类一区| 久久久久国产一级毛片高清牌| 爱豆传媒免费全集在线观看| 69精品国产乱码久久久| 美女主播在线视频| 中文字幕人妻熟女乱码| 777米奇影视久久| 色吧在线观看| 26uuu在线亚洲综合色| 欧美人与性动交α欧美精品济南到 | 1024香蕉在线观看| 亚洲欧美成人精品一区二区| 日韩欧美一区视频在线观看| 晚上一个人看的免费电影| 不卡av一区二区三区| 日日撸夜夜添| 99久久中文字幕三级久久日本| 啦啦啦在线观看免费高清www| 色婷婷av一区二区三区视频| 欧美日韩一级在线毛片| 成人国产麻豆网| 视频区图区小说| 又大又黄又爽视频免费| av免费在线看不卡| 国产精品免费大片| 日韩三级伦理在线观看| 99久久中文字幕三级久久日本| 久久久久久伊人网av| 观看av在线不卡| 欧美精品人与动牲交sv欧美| 国产成人精品久久二区二区91 | 久久国内精品自在自线图片| 久久国产亚洲av麻豆专区| 黄色怎么调成土黄色| 黄色怎么调成土黄色| 久久久久久久精品精品| 黄色毛片三级朝国网站| 热re99久久国产66热| 国产成人a∨麻豆精品| 人妻人人澡人人爽人人| 五月天丁香电影| 热99国产精品久久久久久7| 中文字幕精品免费在线观看视频| 男人爽女人下面视频在线观看| 欧美 亚洲 国产 日韩一| 国产精品熟女久久久久浪| 在线 av 中文字幕| 我的亚洲天堂| 亚洲色图综合在线观看| 我的亚洲天堂| 免费观看无遮挡的男女| 男男h啪啪无遮挡| 午夜91福利影院| 五月天丁香电影| 九色亚洲精品在线播放| 欧美亚洲日本最大视频资源| 成人二区视频| 久久久精品区二区三区| av卡一久久| videossex国产| 午夜免费鲁丝| 色视频在线一区二区三区| 一区二区三区四区激情视频| 91精品国产国语对白视频| 久久韩国三级中文字幕| videossex国产| 亚洲四区av| 国产精品99久久99久久久不卡 | 91在线精品国自产拍蜜月| 黄色毛片三级朝国网站| 好男人视频免费观看在线| 午夜老司机福利剧场| 咕卡用的链子| 男人爽女人下面视频在线观看| 少妇 在线观看| 精品国产超薄肉色丝袜足j| 三上悠亚av全集在线观看| 女人高潮潮喷娇喘18禁视频| av在线老鸭窝| 80岁老熟妇乱子伦牲交| 欧美激情 高清一区二区三区| 日韩,欧美,国产一区二区三区| 90打野战视频偷拍视频| 日本免费在线观看一区| 男女啪啪激烈高潮av片| av福利片在线| 熟女少妇亚洲综合色aaa.| 天美传媒精品一区二区| 午夜福利视频精品| 成人二区视频| 一级爰片在线观看| 日韩一区二区视频免费看| 伦精品一区二区三区| 大香蕉久久网| 久久99一区二区三区| 亚洲美女黄色视频免费看| 最近最新中文字幕免费大全7| 亚洲精品国产色婷婷电影| 免费观看无遮挡的男女| 久久久久网色| 狠狠精品人妻久久久久久综合| av在线app专区| 午夜福利一区二区在线看| 夫妻性生交免费视频一级片| 只有这里有精品99| 国产精品亚洲av一区麻豆 | 欧美亚洲 丝袜 人妻 在线| 亚洲伊人久久精品综合| 亚洲国产精品一区三区| 99久久精品国产国产毛片| 侵犯人妻中文字幕一二三四区| 在线观看www视频免费| 十八禁高潮呻吟视频| 另类亚洲欧美激情| 色网站视频免费| 免费高清在线观看视频在线观看| 久久精品久久久久久噜噜老黄| 熟女少妇亚洲综合色aaa.| 国产1区2区3区精品| 一区二区三区激情视频| 另类精品久久| 丁香六月天网| 宅男免费午夜| 国产免费现黄频在线看| 男的添女的下面高潮视频| 久久这里只有精品19| 成人18禁高潮啪啪吃奶动态图| 美国免费a级毛片| 国产精品久久久久久精品古装| 在线观看一区二区三区激情| 久久久久久久久久久免费av| 性高湖久久久久久久久免费观看| 欧美精品一区二区大全| 久久精品国产自在天天线| 在线观看三级黄色| 黄色怎么调成土黄色| 国产精品久久久久成人av| 性色av一级| 国产一区有黄有色的免费视频| av视频免费观看在线观看| av有码第一页| 日韩一本色道免费dvd| 人人妻人人澡人人看| 一边亲一边摸免费视频| 在线观看美女被高潮喷水网站| 婷婷色综合www| 国产精品一二三区在线看| 久久久国产欧美日韩av| 亚洲精华国产精华液的使用体验| 夫妻性生交免费视频一级片| 亚洲av国产av综合av卡| 亚洲av.av天堂| 中国国产av一级| 校园人妻丝袜中文字幕| 大片免费播放器 马上看| 侵犯人妻中文字幕一二三四区| 亚洲少妇的诱惑av| 国产精品二区激情视频| 中文字幕人妻丝袜制服| 日本wwww免费看| 观看美女的网站| 少妇 在线观看| 美女午夜性视频免费| 国产有黄有色有爽视频| 欧美bdsm另类| 两个人看的免费小视频| 国产精品久久久久成人av| 久久人人97超碰香蕉20202| 亚洲精品美女久久久久99蜜臀 | 国产成人av激情在线播放| 男人爽女人下面视频在线观看| 九九爱精品视频在线观看| 亚洲精华国产精华液的使用体验| 在线天堂最新版资源| 日本午夜av视频| 男女国产视频网站| 日韩免费高清中文字幕av| 欧美日韩亚洲高清精品| 少妇被粗大的猛进出69影院| 欧美最新免费一区二区三区| 久久精品亚洲av国产电影网| 啦啦啦在线观看免费高清www| 男男h啪啪无遮挡| 另类精品久久| 考比视频在线观看| 老司机影院毛片| 波多野结衣一区麻豆| 免费av中文字幕在线| 精品久久久精品久久久| 欧美 日韩 精品 国产| 午夜免费男女啪啪视频观看| 在线天堂最新版资源| 国产成人免费观看mmmm| 综合色丁香网| 人妻系列 视频| 国产伦理片在线播放av一区| 国产精品 国内视频| 国产精品免费大片| av女优亚洲男人天堂| 午夜福利视频在线观看免费| 欧美日本中文国产一区发布| 1024视频免费在线观看| 国产激情久久老熟女| 人妻系列 视频| 九草在线视频观看| 搡女人真爽免费视频火全软件| 久久午夜综合久久蜜桃| 97精品久久久久久久久久精品| 亚洲精品久久成人aⅴ小说| 成人毛片60女人毛片免费| 99热网站在线观看| 99九九在线精品视频| 久久精品国产鲁丝片午夜精品| 久久久国产精品麻豆| 久久久久久伊人网av| 精品国产国语对白av| 老熟女久久久| 亚洲人成77777在线视频| 亚洲av.av天堂| 精品久久久精品久久久| 18禁动态无遮挡网站| 大香蕉久久网| 波多野结衣一区麻豆| 久久97久久精品| 中文字幕制服av| 国产在线免费精品| 一区二区av电影网| 国产成人a∨麻豆精品| 国产精品久久久久久久久免| 国产不卡av网站在线观看| 国产精品 国内视频| 2018国产大陆天天弄谢| 一本久久精品| 国产亚洲精品第一综合不卡| 亚洲人成77777在线视频| 99热国产这里只有精品6| av国产精品久久久久影院| 天堂俺去俺来也www色官网| 国产又色又爽无遮挡免| 午夜日本视频在线| av一本久久久久| 少妇人妻精品综合一区二区| 两个人免费观看高清视频| 如日韩欧美国产精品一区二区三区| 男女国产视频网站| 亚洲精品成人av观看孕妇| 日韩一区二区视频免费看| 亚洲av欧美aⅴ国产| 777米奇影视久久| 在线 av 中文字幕| 精品国产一区二区三区四区第35| 男女免费视频国产| 自拍欧美九色日韩亚洲蝌蚪91| 国产精品熟女久久久久浪| 久久国产精品男人的天堂亚洲| 老鸭窝网址在线观看| www.精华液| 在线免费观看不下载黄p国产| 欧美黄色片欧美黄色片| 中文字幕人妻熟女乱码| 日韩欧美精品免费久久| 赤兔流量卡办理| 亚洲av国产av综合av卡| 色视频在线一区二区三区| 999久久久国产精品视频| 女性生殖器流出的白浆| 国产国语露脸激情在线看| 少妇猛男粗大的猛烈进出视频| 久久人人97超碰香蕉20202| 国产有黄有色有爽视频| 亚洲内射少妇av| 韩国高清视频一区二区三区| www.av在线官网国产| 一级毛片 在线播放| 久久久久精品性色| 免费在线观看完整版高清| 看非洲黑人一级黄片| 国语对白做爰xxxⅹ性视频网站| 日本91视频免费播放| 欧美精品一区二区大全| 两个人看的免费小视频| 欧美成人精品欧美一级黄| 免费看av在线观看网站| 免费大片黄手机在线观看| 精品一区二区三区四区五区乱码 | 国产精品国产三级国产专区5o| 深夜精品福利| 久久精品久久久久久噜噜老黄| 亚洲国产欧美网| tube8黄色片| 国产精品 国内视频| 国产精品女同一区二区软件| 老汉色∧v一级毛片| 久久久国产精品麻豆| 国产男人的电影天堂91| 少妇人妻精品综合一区二区| 亚洲男人天堂网一区| 成人国产av品久久久| 亚洲少妇的诱惑av| 亚洲欧美一区二区三区黑人 | 十八禁高潮呻吟视频| 制服丝袜香蕉在线| 久久午夜综合久久蜜桃| 纯流量卡能插随身wifi吗| 熟女电影av网| 国产亚洲午夜精品一区二区久久| 日韩一区二区三区影片| 九草在线视频观看| 成人国产av品久久久| 在线天堂中文资源库| 美女国产视频在线观看| 男人爽女人下面视频在线观看| 免费看不卡的av| 精品国产乱码久久久久久小说| 精品久久久精品久久久| 久热这里只有精品99| 午夜av观看不卡| 亚洲欧美一区二区三区久久| 欧美在线黄色| 两性夫妻黄色片| av国产久精品久网站免费入址| 精品视频人人做人人爽| 91aial.com中文字幕在线观看| 最近手机中文字幕大全| 亚洲第一青青草原| 26uuu在线亚洲综合色| 欧美日韩精品网址| 欧美日本中文国产一区发布| 最近最新中文字幕免费大全7| 国产日韩欧美视频二区| 丝袜美腿诱惑在线| 中国国产av一级| 国产亚洲av片在线观看秒播厂| 两性夫妻黄色片| 下体分泌物呈黄色| 国产在线免费精品| 亚洲国产欧美在线一区| 久久精品久久久久久久性| 熟女电影av网| 两个人看的免费小视频| 男的添女的下面高潮视频| 日本猛色少妇xxxxx猛交久久| 欧美成人精品欧美一级黄| 国产成人精品无人区| av国产精品久久久久影院| 美女中出高潮动态图| 少妇被粗大猛烈的视频| 欧美人与性动交α欧美软件| 深夜精品福利| 大码成人一级视频| 亚洲国产成人一精品久久久| 亚洲av欧美aⅴ国产| 国产成人a∨麻豆精品| 人妻 亚洲 视频| 亚洲美女视频黄频| 狂野欧美激情性bbbbbb| 国产成人精品福利久久| 亚洲精品国产一区二区精华液| 久热久热在线精品观看| 肉色欧美久久久久久久蜜桃| 青青草视频在线视频观看| 午夜福利视频在线观看免费| 欧美亚洲 丝袜 人妻 在线| 一区二区三区乱码不卡18| kizo精华| 成人国产av品久久久| 亚洲精品一二三| 一级毛片 在线播放| 亚洲精品在线美女| 永久网站在线| 久久97久久精品| 久久精品aⅴ一区二区三区四区 | 成人漫画全彩无遮挡| 亚洲少妇的诱惑av| 一区在线观看完整版| 97精品久久久久久久久久精品| 亚洲人成77777在线视频| 国产视频首页在线观看| 国产亚洲av片在线观看秒播厂| 亚洲熟女精品中文字幕| 国产黄色视频一区二区在线观看| 色网站视频免费| 亚洲精品av麻豆狂野| 国产色婷婷99| 超色免费av| 亚洲欧美中文字幕日韩二区| 亚洲人成77777在线视频| 两个人看的免费小视频| 巨乳人妻的诱惑在线观看| 最新中文字幕久久久久| 一级黄片播放器| 国产成人精品无人区| 亚洲国产最新在线播放| 久久精品国产亚洲av涩爱| 男女高潮啪啪啪动态图| 欧美av亚洲av综合av国产av | 国产精品成人在线| 水蜜桃什么品种好| 熟女电影av网| 美女福利国产在线| 欧美人与善性xxx| 男女高潮啪啪啪动态图| 91成人精品电影| 少妇人妻 视频| 妹子高潮喷水视频| 日韩av不卡免费在线播放| 日韩免费高清中文字幕av| 在线天堂中文资源库| 伦理电影免费视频| 巨乳人妻的诱惑在线观看| 亚洲欧洲国产日韩| 香蕉精品网在线| av免费在线看不卡| 国产免费视频播放在线视频| 欧美黄色片欧美黄色片| 国产片内射在线| 日韩精品免费视频一区二区三区| 亚洲av男天堂| 久久久久久人妻| 亚洲精品自拍成人| 老司机影院成人| 美女脱内裤让男人舔精品视频| 国产成人免费无遮挡视频| 国产精品二区激情视频| 国产视频首页在线观看| 美女午夜性视频免费| 亚洲国产av影院在线观看| 飞空精品影院首页| av在线观看视频网站免费| 亚洲精品日本国产第一区| 精品国产露脸久久av麻豆| 美女福利国产在线| 捣出白浆h1v1| 日韩三级伦理在线观看| 97精品久久久久久久久久精品| 黄频高清免费视频| 精品少妇久久久久久888优播| av线在线观看网站| 国产精品一国产av| 国产精品一二三区在线看| 国产成人精品久久久久久| 午夜老司机福利剧场| 国产免费现黄频在线看| 一区二区三区四区激情视频| 欧美黄色片欧美黄色片| 欧美精品av麻豆av| 另类亚洲欧美激情| 亚洲欧洲日产国产| 久久婷婷青草| 国产男女内射视频| 日韩视频在线欧美| 大码成人一级视频| 一级爰片在线观看| 可以免费在线观看a视频的电影网站 | 少妇人妻久久综合中文| 亚洲美女搞黄在线观看| 国产极品粉嫩免费观看在线| 欧美成人精品欧美一级黄| 国产 一区精品| 啦啦啦啦在线视频资源| 汤姆久久久久久久影院中文字幕| 一二三四在线观看免费中文在| 欧美精品人与动牲交sv欧美| 美女国产高潮福利片在线看| 国产成人精品久久久久久| 免费在线观看视频国产中文字幕亚洲 | 久久久久久人人人人人| 91aial.com中文字幕在线观看| 亚洲av综合色区一区| 国产精品一国产av| 欧美亚洲日本最大视频资源| 国产一区二区三区av在线| 欧美 日韩 精品 国产| 婷婷色综合大香蕉| 狠狠精品人妻久久久久久综合| 久久久久精品久久久久真实原创| 成年av动漫网址| 日本vs欧美在线观看视频| 91成人精品电影| 欧美精品国产亚洲| 80岁老熟妇乱子伦牲交| av天堂久久9| 日韩,欧美,国产一区二区三区| 免费观看无遮挡的男女| 国产男女超爽视频在线观看| 99久久精品国产国产毛片| 久久免费观看电影| 久热久热在线精品观看| 久久精品久久久久久噜噜老黄| 老女人水多毛片| 又粗又硬又长又爽又黄的视频| 日韩一区二区视频免费看|